Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Chronic Heart Failure

Free Subscription 16.03.2026 5 Am Heart J 5 Am J Cardiol 1 Ann Thorac Surg 1 BMJ 1 Circ Heart Fail 2 Circ Res 2 Circulation 7 Eur Heart J 51 Eur J Heart Fail 5 Heart 1 Hypertension 3 Int J Cardiol 18 J Card Fail 2 J Cardiol 1 J Mol Cell Cardiol 1 N Engl J Med 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am Heart J

1. ELLABBAD M, Kholeif Z, Ammash NM, Dunlay SM, et al
   Adults with Repaired Systemic Biventricular Congenital Heart Disease with a Systemic Left Ventricle and Heart Failure with Reduce Ejection Fraction.
   Am Heart J. 2026 Mar 7:107422. doi: 10.1016/j.ahj.2026.107422.
   PubMed         Abstract available
   
   
2. LARSEN JH, Andersen CF, Jessen MM, Hansen MC, et al
   Empagliflozin and Functional Aerobic Capacity in Individuals with Increased Risk of Heart Failure: The Empire Prevent Cardiac Trial.
   Am Heart J. 2026 Mar 7:107398. doi: 10.1016/j.ahj.2026.107398.
   PubMed         Abstract available
   
   
3. CANTU-MARTINEZ O, Fudim M, Kong DF, Tedford RJ, et al
   Accuracy of site versus core laboratory interpretations of right heart catheterization hemodynamics.
   Am Heart J. 2026;295:107351.
   PubMed         Abstract available
   
   
4. KALMUCKI P, Lipiecki J, Witte KK, Goldberg SL, et al
   Percutaneous mitral annuloplasty with the Carillon device: outcomes in proportionate and disproportionate functional mitral regurgitation.
   Am Heart J. 2023 Jul 27:S0002-8703(23)00181-3. doi: 10.1016/j.ahj.2023.
   PubMed         Abstract available
   
   
5. SHAH NP, Peterson ED, Page C, Blanco R, et al
   Generalizability of an EHR-Network Dataset to the United States for Cardiovascular Disease Conditions: Comparison of Cerner Real World Data with the National Inpatient Sample.
   Am Heart J. 2023 May 15:S0002-8703(23)00120-5. doi: 10.1016/j.ahj.2023.
   PubMed         Abstract available
   
   

   
   Am J Cardiol

6. INOUE N, Morikawa S, Murohara T
   Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Supra-normal Ejection Fraction: A Target Trial Emulation Study.
   Am J Cardiol. 2026 Feb 28:S0002-9149(26)00098.
   PubMed         Abstract available
   
   
7. SIDERIS K, Bunsawat K, Brinker L, Braun E, et al
   The Effect of Vericiguat on Endothelial Function in Patients with Heart Failure with Reduced Ejection Fraction: A Pilot Randomized Study.
   Am J Cardiol. 2026 Feb 27:S0002-9149(26)00114.
   PubMed         Abstract available
   
   
8. GHIO S, Carluccio E, Franzese M, Acquaro M, et al
   Prognostic thresholds of pulmonary artery pressure and right ventricular function at echocardiography in heart failure.
   Am J Cardiol. 2026 Feb 27:S0002-9149(26)00102.
   PubMed         Abstract available
   
   
9. RUANGSUBVILAI N, Au-Yeung K, Wongbuddha C, Shechter A, et al
   Outcomes of Patients with Mitral Stenosis with Prior Percutaneous Mitral Commissurotomy Undergoing Mitral Valve Surgery.
   Am J Cardiol. 2026 Jan 19:S0002-9149(26)00010.
   PubMed         Abstract available
   
   
10. MOURA A, Baliafa E, Alexandropoulos C, Papazoglou AS, et al
    Association of Length of Stay With the Clinical Trajectory of Hospitalized Patients With Atrial Fibrillation: Staying Less Is More?
    Am J Cardiol. 2023;206:254-261.
    PubMed         Abstract available
    
    

    
    Ann Thorac Surg

11. ASHFAQ A, Lorts A, Rosenthal D, Adachi I, et al
    Survival in Pediatric Patients With Ventricular Assist Devices: A Special Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report.
    Ann Thorac Surg. 2023;116:972-979.
    PubMed         Abstract available
    
    

    
    BMJ

12. MILES LM, Luckham K, Mills J, Mindham R, et al
    Chronic heart failure in adults: diagnosis and management-summary of updated NICE guidance.
    BMJ. 2026;392:s266.
    PubMed        
    
    

    
    Circ Heart Fail

13. SHAKIL SS, Hsue PY
    Heart Failure Risk in HIV: From Immunodeficiency to Metabolic Complexity.
    Circ Heart Fail. 2026 Mar 11:e014088. doi: 10.1161/CIRCHEARTFAILURE.126.014088.
    PubMed        
    
    

    
    Circ Res

14. HORNER KB, Mutchler AL
    Indole Loss: Hypertensive Link Between Dysbiosis and Diastolic Heart Failure.
    Circ Res. 2026;138:e328284.
    PubMed        
    
    
15. ZAKARAUSKAS-SETH BI, Forcari G, Anandakumar H, Kotlar-Goldaper I, et al
    Indole-3 Acetate Limits Dysbiosis-Driven Diastolic Failure via Hcrt Neurons.
    Circ Res. 2026;138:e326990.
    PubMed         Abstract available
    
    

    
    Circulation

16. LEI J, Zhang F, Wang J
    Correction to: Letter by Lei et al Regarding Article, "A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure".
    Circulation. 2026;153:e934.
    PubMed        
    
    
17. MARTIN TG, Hunt DR, Ebmeier CC, Dhand AP, et al
    Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D.
    Circulation. 2026;153:673-687.
    PubMed         Abstract available
    
    

    
    Eur Heart J

18. REITSMA TH, Lim CE, Gynnild MN, Kaptoge S, et al
    Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.
    Eur Heart J. 2026 Mar 11:ehag153. doi: 10.1093.
    PubMed         Abstract available
    
    
19. TORP-PEDERSEN C, Kragholm KH, Kober L
    Risk Scores for Heart Failure: Powerful for Populations, Problematic for the individual Patient.
    Eur Heart J. 2026 Mar 11:ehag183. doi: 10.1093.
    PubMed        
    
    
20. 
    Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.
    Eur Heart J. 2026 Mar 11:ehag154. doi: 10.1093.
    PubMed         Abstract available
    
    
21. REITSMA TH, Savarese G, Kuzma L, Deo SV, et al
    Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model.
    Eur Heart J. 2026 Mar 11:ehag182. doi: 10.1093.
    PubMed         Abstract available
    
    
22. BORLAUG BA, Zile MR, Packer M
    Visceral adiposity assessment to enhance risk stratification in heart failure with preserved ejection fraction.
    Eur Heart J. 2026 Mar 6:ehag119. doi: 10.1093.
    PubMed        
    
    
23. CHARRON P, Proukhnitzky J, Ben Yaou R, Richard P, et al
    Laminopathies: natural history and risk prediction of heart failure.
    Eur Heart J. 2026 Mar 6:ehag104. doi: 10.1093.
    PubMed         Abstract available
    
    
24. KANEKO T, Kagiyama N, Okazaki S, Amano M, et al
    Transcatheter edge-to-edge repair vs medical therapy in atrial functional mitral regurgitation: a propensity score-based comparison from the OCEAN-Mitral and REVEAL-AFMR registries.
    Eur Heart J. 2025 Jul 9:ehaf511. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Eur J Heart Fail

25. VAN DER MEER P, Voordes GHD, Vijver MAT, Mosterd A, et al
    Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial.
    Eur J Heart Fail. 2026 Mar 13:xuag073. doi: 10.1093.
    PubMed         Abstract available
    
    
26. RAKISHEVA A, Suleimenov E, Akanova A, Raissova A, et al
    Editorial comment to: Influenza Vaccination in Acute Heart Failure: A Simple Shield for the "Vulnerable Phase".
    Eur J Heart Fail. 2026 Mar 12:xuag058. doi: 10.1093.
    PubMed        
    
    
27. MARTENS P, Olivotto I, Garcia-Pavia P, Michels M, et al
    Comprehensive evaluation of hypertrophic cardiomyopathy: European Journal of Heart Failure expert consensus document.
    Eur J Heart Fail. 2026 Mar 12:xuag035. doi: 10.1093.
    PubMed         Abstract available
    
    
28. HAMATANI Y, Peikert A, Claggett BL, Desai AS, et al
    Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.
    Eur J Heart Fail. 2026 Mar 12:xuag062. doi: 10.1093.
    PubMed         Abstract available
    
    
29. NISHINO M, Egami Y, Mukai T, Kise M, et al
    Are beta-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry.
    Eur J Heart Fail. 2026 Mar 11:xuag071. doi: 10.1093.
    PubMed         Abstract available
    
    
30. LAUDER L, Staub D, Mahfoud F
    Renal artery stenosis in heart failure: the overlooked cardiorenal culprit?
    Eur J Heart Fail. 2026 Mar 9:xuag070. doi: 10.1093.
    PubMed        
    
    
31. REDDY YNV, Oduah MT, Adel F, Miranda WR, et al
    Very High Dose Loop Diuretics for Worsening Heart Failure - A Randomized Pilot Trial.
    Eur J Heart Fail. 2026 Mar 9:xuag069. doi: 10.1093.
    PubMed        
    
    
32. CHAI Y, Wang D
    Letter regarding the article 'Beta-blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes'.
    Eur J Heart Fail. 2026 Mar 9:xuag065. doi: 10.1093.
    PubMed        
    
    
33. BEER BN, Lindberg F, Savarese G
    Letter to the Editor answering to Chai and Wang Beta-blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: cardiovascular and respiratory outcomes.
    Eur J Heart Fail. 2026 Mar 6:xuag066. doi: 10.1093.
    PubMed        
    
    
34. MYHRE PL, Lindberg F, Logstrup BB, Ingimarsdottir IJ, et al
    Enhancing Heart Failure Care Through Registries: Lessons Learned from Nordic Countries' Implementation of Guidelines.
    Eur J Heart Fail. 2026 Mar 5:xuag060. doi: 10.1093.
    PubMed         Abstract available
    
    
35. FOX SJ, Champsi A, Hardy EJ, Bunting KV, et al
    Combination of heart failure and atrial fibrillation worsens ethnicity-related disparity: an individual patient-level meta-analysis of randomized trials.
    Eur J Heart Fail. 2026 Feb 24:xuag017. doi: 10.1093.
    PubMed         Abstract available
    
    
36. YILMAZ MB, Metra M
    Evidence-based medical therapy after structural interventions: when remaining proactive for heart failure medications can save lives.
    Eur J Heart Fail. 2026 Feb 19:xuag001. doi: 10.1093.
    PubMed        
    
    
37. OSMANSKA J, Petrie MC, Biegus J
    Severe kidney disease and heart failure therapy: a conundrum only partially resolved.
    Eur J Heart Fail. 2026 Feb 19:xuag012. doi: 10.1093.
    PubMed        
    
    
38. GUZIK M, Zymlinski R, Biegus J
    Sodium-glucose cotransporter-2 inhibitors in heart failure. How durable is the decongestive effect?
    Eur J Heart Fail. 2026 Feb 18:xuaf019. doi: 10.1093.
    PubMed        
    
    
39. NASER JA, Rahme SJ, Castrichini M, Ibrahim H, et al
    Impact of contemporary guideline-directed medical therapy on secondary mitral and tricuspid regurgitation in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2026 Feb 19:xuag047. doi: 10.1093.
    PubMed         Abstract available
    
    
40. ALNUWAYSIR RIS, Bomer N, Anker SD, van Veldhuisen DJ, et al
    Iron Deficiency Definitions and their Clinical and Prognostic Associations Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure.
    Eur J Heart Fail. 2026 Feb 2:xuag031. doi: 10.1093.
    PubMed         Abstract available
    
    
41. FOA A, Vaduganathan M, Claggett BL, Diaz R, et al
    Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
    Eur J Heart Fail. 2026 Feb 12:xuag023. doi: 10.1093.
    PubMed         Abstract available
    
    
42. EL-HADIDI S, Lindberg F, Benson L, Uijl A, et al
    Magnitude of and outcome associated with inappropriate prescribing in heart failure with reduced ejection fraction: an analysis of 50 348 patients from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2026 Jan 14:xuaf026. doi: 10.1093.
    PubMed         Abstract available
    
    
43. BEER BN, Kellner C, Sundermeyer J, Besch L, et al
    Balancing blood pressure and catecholamine support is critical in heart failure-related cardiogenic shock patients.
    Eur J Heart Fail. 2026 Jan 14:xuag009. doi: 10.1093.
    PubMed         Abstract available
    
    
44. BAYES-GENIS A, Schiattarella GG
    Beyond BMI: why heart failure trials must quantify adiposity, not just obesity.
    Eur J Heart Fail. 2026 Feb 17:xuag046. doi: 10.1093.
    PubMed        
    
    
45. BAYES-GENIS A, Codina P, Santiago E, Ruiz-Cueto M, et al
    Real-world improved, remission, and recovered heart failure: long-term follow-up outcomes.
    Eur J Heart Fail. 2026 Jan 14:xuaf024. doi: 10.1093.
    PubMed        
    
    
46. RAKISHEVA A, Biegus J, Chioncel O
    Congestion in acute heart failure: a moving target in transition.
    Eur J Heart Fail. 2026 Feb 17:xuaf013. doi: 10.1093.
    PubMed        
    
    
47. IVARS-OBERMEIER N, Llorens P, Castells X, Muller C, et al
    Effect of influenza vaccination in patients with decompensated heart failure: a systematic review and meta-analysis.
    Eur J Heart Fail. 2026 Jan 12:xuaf025. doi: 10.1093.
    PubMed         Abstract available
    
    
48. CAMPBELL RT, Osmanska J, Docherty KF, Ahmed FZ, et al
    SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart Failure.
    Eur J Heart Fail. 2026 Jan 12:xuaf018. doi: 10.1093.
    PubMed         Abstract available
    
    
49. GREEN D, Cleland JGF, Pellicori P, O'Keeffe H, et al
    Revascularization of atherosclerotic renal artery stenosis in patients with heart failure.
    Eur J Heart Fail. 2026 Feb 11:xuag042. doi: 10.1093.
    PubMed         Abstract available
    
    
50. HAMATANI Y, Claggett BL, Kulac IJ, Desai AS, et al
    Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial.
    Eur J Heart Fail. 2026 Feb 10:xuag030. doi: 10.1093.
    PubMed         Abstract available
    
    
51. YOON M, Park JJ, Greenberg B
    Finerenone and polypharmacy in heart failure with mildly reduced or preserved ejection fraction: a marker of risk, not a barrier to therapy.
    Eur J Heart Fail. 2026 Feb 10:xuag025. doi: 10.1093.
    PubMed        
    
    
52. BIEGUS J, Bayes-Genis A, von Haehling S, Kosmala W, et al
    Contemporary heart failure evidence in 2025: a joint summary of key trials from the European Journal of Heart Failure and ESC Heart Failure Journal.
    Eur J Heart Fail. 2026 Jan 17:xuag015. doi: 10.1093.
    PubMed         Abstract available
    
    
53. SIDDIQI TJ, Khan MS, Fonarow GC, Butler J, et al
    Reply to commentary on 'effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular kidney-metabolic comorbidity'.
    Eur J Heart Fail. 2026 Jan 8:xuaf004. doi: 10.1093.
    PubMed        
    
    
54. MONZO L, Savarese G, Mullens W, Abdelhamid M, et al
    Implementation of guideline-directed medical therapy in patients with heart failure and obesity: European Journal of Heart Failure expert consensus document.
    Eur J Heart Fail. 2026 Feb 4:xuag027. doi: 10.1093.
    PubMed         Abstract available
    
    
55. SANDERSON JE, Cleland JGF
    The current classification of heart failure is obsolete.
    Eur J Heart Fail. 2026 Jan 8:xuaf010. doi: 10.1093.
    PubMed        
    
    
56. DHONT S, Bertrand PB
    Heart rate modulation in heart failure with preserved ejection fraction: lessons from nature.
    Eur J Heart Fail. 2026 Jan 17:xuag016. doi: 10.1093.
    PubMed        
    
    
57. SLIWA K, Viljoen C, Hoevelmann J, Rakisheva A, et al
    Access to medical care globally for patients with peripartum cardiomyopathy: a clinical consensus statement of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2026 Jan 29:xuag024. doi: 10.1093.
    PubMed         Abstract available
    
    
58. 
    Correction to: An expert opinion on heart failure in hypertensive heart disease.
    Eur J Heart Fail. 2026 Feb 12:xuag040. doi: 10.1093.
    PubMed        
    
    
59. AIMO A, Tomasoni D, Fontana M
    Possible ways of building trial-level evidence for heart failure therapies in cardiac amyloidosis.
    Eur J Heart Fail. 2026 Jan 21:xuag019. doi: 10.1093.
    PubMed        
    
    
60. WANG N, Hibbert T, Ishak S, Raftopulos N, et al
    Surrogate markers of clinical endpoints in clinical trials of heart failure.
    Eur J Heart Fail. 2026 Feb 6:xuag033. doi: 10.1093.
    PubMed         Abstract available
    
    
61. ONO R, Chimura M, Docherty KF, Jhund PS, et al
    Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF.
    Eur J Heart Fail. 2026 Jan 13:xuag003. doi: 10.1093.
    PubMed         Abstract available
    
    
62. DIEZ J, Gonzalez A, Kirabo A, Verdecchia P, et al
    An expert opinion on heart failure in hypertensive heart disease.
    Eur J Heart Fail. 2026 Jan 13:xuag004. doi: 10.1093.
    PubMed         Abstract available
    
    
63. VASQUES-NOVOA F, Ferreira JP, Mancio J, Marques P, et al
    Myocardial fibrosis in heart failure with preserved ejection fraction: integrating circulating collagen fragments and cardiac magnetic resonance mapping.
    Eur J Heart Fail. 2026 Jan 12:xuaf020. doi: 10.1093.
    PubMed        
    
    
64. LIANG Y, Wang X, Meng Z
    Commentary on 'effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity'.
    Eur J Heart Fail. 2026 Jan 23:xuaf022. doi: 10.1093.
    PubMed        
    
    
65. LEE J, Cheon S, Kang ES, Song J, et al
    Coexistence of atrial fibrillation and metabolic dysfunction-associated steatotic liver disease as a high-risk overlap for incident heart failure in older adults.
    Eur J Heart Fail. 2026 Feb 10:xuag036. doi: 10.1093.
    PubMed         Abstract available
    
    
66. BUNTING KV, Tica O, Champsi A, Perrett M, et al
    Erythropoiesis-stimulating agents to reduce heart failure hospitalization: a systematic review and meta-analysis.
    Eur J Heart Fail. 2026 Jan 8:xuaf012. doi: 10.1093.
    PubMed         Abstract available
    
    
67. NUNEZ-MARIN G, de la Espriella R, Llacer P, Palau P, et al
    Prognostic value of early changes in NT-proBNP across left ventricular ejection fraction status in acute heart failure.
    Eur J Heart Fail. 2026 Jan 21:xuag018. doi: 10.1093.
    PubMed         Abstract available
    
    
68. SCHULZ M, Laufs U
    Challenges of heart failure pharmacotherapy in obesity.
    Eur J Heart Fail. 2026 Jan 30:xuag011. doi: 10.1093.
    PubMed        
    
    
69. VON PETER A, Stolte T, Goetzinger F, Reichl JJ, et al
    Incidence and management of heart failure phenotypes in patients undergoing transcatheter aortic valve implantation.
    Eur J Heart Fail. 2026 Jan 8:xuaf015. doi: 10.1093.
    PubMed        
    
    
70. CHIMURA M, Jhund PS, Henderson AD, Claggett BL, et al
    Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial.
    Eur J Heart Fail. 2026 Jan 14:xuag008. doi: 10.1093.
    PubMed         Abstract available
    
    
71. RUBIS P, Dziewiecka E, Banys R, Lisiecka M, et al
    Effects of sodium-glucose cotransporter 2 inhibitors on cardiac metabolism, assessed by phosphorus magnetic resonance spectroscopy, in patients with heart failure.
    Eur J Heart Fail. 2026 Jan 23:xuag026. doi: 10.1093.
    PubMed        
    
    
72. SHEN L, Shen L, Cheang I, Yao W, et al
    The efficacy and safety of qiliqiangxin according to baseline ejection fraction in patients with heart failure and reduced ejection fraction in QUEST.
    Eur J Heart Fail. 2026 Jan 12:xuaf017. doi: 10.1093.
    PubMed         Abstract available
    
    
73. IWANEK G, Zymlinski R, Guzik M, Gajewski P, et al
    The impact of volume and sodium chloride supplementation on diuretic response during decongestion of decompensated heart failure patients.
    Eur J Heart Fail. 2026 Jan 12:xuaf023. doi: 10.1093.
    PubMed         Abstract available
    
    
74. CHIMURA M, Docherty KF, Jhund PS, Yang M, et al
    Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF.
    Eur J Heart Fail. 2026 Jan 14:xuag007. doi: 10.1093.
    PubMed         Abstract available
    
    
75. FERREIRA JP, Zannad F, Butler J, Filippatos G, et al
    Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.
    Eur J Heart Fail. 2026 Feb 28:xuag054. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Heart

76. 
    Correction: Atrial fibrillation and heart failure with preserved ejection fraction: diagnostic challenges and therapeutic opportunities.
    Heart. 2026;112:e3.
    PubMed        
    
    
77. MARIANI A, Luckham K, Miles L, Samarasekera E, et al
    Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction.
    Heart. 2026 Mar 11:heartjnl-2025-327190. doi: 10.1136/heartjnl-2025-327190.
    PubMed         Abstract available
    
    
78. AVERBUCH T, Greene S, Biering-Sorensen T, Kotwal S, et al
    Burden of chronic kidney disease and outcomes following hospitalisation for heart failure.
    Heart. 2026 Mar 3:heartjnl-2025-327053. doi: 10.1136/heartjnl-2025-327053.
    PubMed         Abstract available
    
    
79. KOBAYASHI M
    Kidney decline: an overlooked driver of mortality and healthcare burden following heart failure hospitalisation.
    Heart. 2026 Mar 3:heartjnl-2025-327647. doi: 10.1136/heartjnl-2025-327647.
    PubMed        
    
    
80. NEDEREND M, Kies P, Regeer MV, Vliegen HW, et al
    Tolerability and beneficial effects of sacubitril/valsartan on systemic right ventricular failure.
    Heart. 2023;109:1525-1532.
    PubMed         Abstract available
    
    

    
    Hypertension

81. LIU L, Ren GM, Chen C, Liu GY, et al
    BRISC Deficiency Drives Heart Failure by Regulating beta-Catenin K63 Ubiquitination.
    Hypertension. 2026 Mar 6. doi: 10.1161/HYPERTENSIONAHA.125.25727.
    PubMed         Abstract available
    
    

    
    Int J Cardiol

82. KOK TF, Kamar SA, Suthahar N, Wemelsfelder S, et al
    Serially measured blood biomarkers collected in the context of usual care, predict clinical outcome in a real-life heart failure population.
    Int J Cardiol. 2026 Mar 10:134289. doi: 10.1016/j.ijcard.2026.134289.
    PubMed         Abstract available
    
    
83. IACOVIELLO M, Scicchitano P, Massari F
    The role of inflammatory biomarkers in acute heart failure: Between prediction and action.
    Int J Cardiol. 2026 Mar 6:134271. doi: 10.1016/j.ijcard.2026.134271.
    PubMed        
    
    
84. SCICCHITANO P, Massari F
    Cardiac rehabilitation in heart failure and coronary artery disease: Improving healthcare system.
    Int J Cardiol. 2026;451:134253.
    PubMed        
    
    

    
    J Card Fail

85. MARGULIES KB
    Advancing Genetics and Heart Failure: HFSA Steps Forward to Lead.
    J Card Fail. 2026;32:693.
    PubMed        
    
    
86. 
    HF Stats: Your Source for Citable, Shareable Heart Failure Data.
    J Card Fail. 2026;32:691-692.
    PubMed        
    
    
87. NAGANO T, Tanaka H, Fujimoto W, Yokota H, et al
    Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort.
    J Card Fail. 2026 Mar 9:S1071-9164(26)00146.
    PubMed         Abstract available
    
    
88. WONG J, Chen L, Magliano DJ, Morton JI, et al
    Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer.
    J Card Fail. 2026 Mar 9:S1071-9164(26)00145.
    PubMed         Abstract available
    
    
89. BUTLER J, Rao I, Sauer AJ, Anker SD, et al
    Cardiac Contractility Modulation for Patients with Heart Failure and Preserved Ejection Fraction: The AIM HIGHer Study.
    J Card Fail. 2026 Mar 7:S1071-9164(26)00155.
    PubMed        
    
    
90. MARTILLO-CORREA M, Agdamag AC, Zingano CP, Spiazzi BF, et al
    Don't Forget the Brain: Optimizing Brain Health as a Treatment Target in Heart Failure.
    J Card Fail. 2026 Mar 6:S1071-9164(26)00084.
    PubMed        
    
    
91. BEKFANI T, Simonsen JO, Fussing FH, Christensen J, et al
    Remote Patient Care of Patients with Heart Failure: A Focused Review on the HeartLogic-System.
    J Card Fail. 2026 Mar 4:S1071-9164(26)00097.
    PubMed         Abstract available
    
    
92. MARTYN T, Chedid El Helou M, Zalaquett Z, Rajendran J, et al
    The Association of Guideline-Directed Medical Therapy Scores and Patient Outcomes in Patients With Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction.
    J Card Fail. 2026 Mar 3:S1071-9164(26)00085.
    PubMed         Abstract available
    
    
93. MANN DL
    The Cardio-Hematopoietic Axis in Heart Failure With Preserved Ejection Fraction: A Theory of Everything?
    J Card Fail. 2026 Mar 2:S1071-9164(26)00087.
    PubMed        
    
    
94. TAFFESSE BG, Ambrosy AP
    FAIR Enough for All? Intravenous Iron in Ischemic and Nonischemic Heart Failure with Reduced Ejection Fraction.
    J Card Fail. 2026 Mar 1:S1071-9164(26)00108.
    PubMed        
    
    
95. ISMAIL A, Erne G, Vasbinder A, Hutten CG, et al
    Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients with Diabetes and Heart Failure: A SOLOIST-WHF Ancillary Study.
    J Card Fail. 2026 Feb 28:S1071-9164(26)00105.
    PubMed         Abstract available
    
    
96. HYUN J, Kim IC, Kim AR, Lee HJ, et al
    High versus Low Positive End-Expiratory Pressure in Mechanically Ventilated Patients with Acute Heart Failure: The HELP-AHF Randomized Clinical Trial.
    J Card Fail. 2026 Feb 27:S1071-9164(26)00104.
    PubMed        
    
    
97. LABIN JE, Kapadia SR, Reardon MJ, Puri R, et al
    Heterotopic Heart Valve Implantation for Caval Reflux: A Novel Strategy to Bridge the Therapeutic Gap in Severe Tricuspid Regurgitation with Right Heart Failure.
    J Card Fail. 2026 Feb 27:S1071-9164(26)00110.
    PubMed        
    
    
98. REDDY YNV, Lee JK
    The Ever Reliable Pulmonary Artery Pressure and the Quest for Less Invasive Surrogates in Heart Failure.
    J Card Fail. 2026 Feb 26:S1071-9164(26)00095.
    PubMed        
    
    
99. FERREIRA JP, Marques P, Leite AR, Neves JS, et al
    Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors: Agent Comparison With Implications for Clinical Practice and Trial Design.
    J Card Fail. 2026;32:633-646.
    PubMed         Abstract available
    
    
100. JERING KS, Claggett BL, Braunwald E, Granger CB, et al
     NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial.
     J Card Fail. 2026;32:586-595.
     PubMed         Abstract available
     
     
101. DEFILIPPIS EM, Truby LK, Garg S, Wu E, et al
     Predicted Heart Mass and Outcomes in the Contemporary Era of Heart Transplantation: Insights from the Dallas Heart Study.
     J Card Fail. 2026;32:608-615.
     PubMed         Abstract available
     
     
102. SHARMA A, Marques P, Zhang G, Oulousian E, et al
     Voice-assisted Artificial Intelligence-enabled Screening for Severe Acute Respiratory Syndrome Coronavirus 2 Exposure in Cardiovascular Clinics: Primary Results of the VOICE-COVID-19-II Randomized Trial.
     J Card Fail. 2023;29:1456-1460.
     PubMed         Abstract available
     
     

     
     J Cardiol

103. YANO M, Egami Y, Kise M, Mukai T, et al
     Prognostic significance of blood urea nitrogen-to-albumin ratio in heart failure: From baseline and age-specific risk stratification to one-year dynamic changes.
     J Cardiol. 2026 Mar 5:S0914-5087(26)00044-4. doi: 10.1016/j.jjcc.2026.
     PubMed         Abstract available
     
     
104. SAITO Y, Obokata M
     Author's reply: An evidence-based tool for screening for heart failure with preserved ejection fraction in primary care: The BREATH2 score: Discussion from a statistical perspective.
     J Cardiol. 2026 Mar 5:S0914-5087(26)00046-8. doi: 10.1016/j.jjcc.2026.
     PubMed        
     
     

     
     J Mol Cell Cardiol

105. PALIOURA D, Mellidis K, Ioannidou-Kabouri K, Galatou E, et al
     PPARdelta activation improves cardiac mitochondrial homeostasis in desmin deficient mice but does not alleviate systolic dysfunction.
     J Mol Cell Cardiol. 2023;183:27-41.
     PubMed         Abstract available
     
     

     
     N Engl J Med

106. NIJVELDT R, Maeng M, Beijnink CWH, Piek JJ, et al
     Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.
     N Engl J Med. 2025 Oct 28. doi: 10.1056/NEJMoa2512918.
     PubMed         Abstract available
     
     

     
     PLoS One

107. KONO Y, Sonoda K, Ohtake K, Ota A, et al
     Early administration of renin-angiotensin system inhibitors improves survival and cardiac remodeling in heart failure with preserved ejection fraction.
     PLoS One. 2026;21:e0339600.
     PubMed         Abstract available
     
     
108. BORKOWSKI P, Biavati L, Nazarenko N, Parker M, et al
     Racial differences in people living with HIV and Heart Failure: Insight from New York City health and hospitals HIV Heart Failure Cohort.
     PLoS One. 2026;21:e0343710.
     PubMed         Abstract available
     
     
109. DU Y, Wang N, Dong J, Chai X, et al
     Gastrin ameliorates heart failure and suppresses myocardial remodeling via the JAK2/STAT3 and ERK1/2 pathways.
     PLoS One. 2026;21:e0343403.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum